Trial Profile
Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Contusugene ladenovec (Primary) ; Cisplatin; Paclitaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Shenzhen SiBiono GeneTech
- 05 May 2015 New trial record